SRTS - Sensus Healthcare Inc Stock Price, Fair Value and News

3.63USD-0.23 (-5.96%)Market Closed

Market Summary

USD3.63-0.23

Market Closed

-5.96%

SRTS Stock Price

View Fullscreen

SRTS RSI Chart

SRTS Valuation

Market Cap

59.5M

Price/Earnings (Trailing)

122.7

Price/Sales (Trailing)

2.44

EV/EBITDA

-555.16

Price/Free Cashflow

-25.07

SRTS Price/Sales (Trailing)

SRTS Profitability

EBT Margin

2.67%

Return on Equity

0.99%

Return on Assets

0.9%

Free Cashflow Yield

-3.99%

SRTS Fundamentals

SRTS Revenue

Revenue (TTM)

24.4M

Rev. Growth (Yr)

-4.1%

Rev. Growth (Qtr)

222.38%

SRTS Earnings

Earnings (TTM)

485.0K

Earnings Growth (Yr)

48.82%

Earnings Growth (Qtr)

390.14%

Breaking Down SRTS Revenue

Last 7 days

6.5%

Last 30 days

2.5%

Last 90 days

14.9%

Trailing 12 Months

33.5%

How does SRTS drawdown profile look like?

SRTS Financial Health

Current Ratio

11.76

SRTS Investor Care

Buy Backs (1Y)

0.02%

Diluted EPS (TTM)

0.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	37.6M	30.1M	24.9M	24.4M
2022	31.4M	35.8M	40.2M	44.5M
2021	11.0M	0	0	27.0M
2020	23.5M	17.2M	13.0M	9.6M
2019	25.9M	27.3M	26.8M	27.3M
2018	22.2M	23.3M	24.8M	26.4M
2017	16.1M	17.5M	19.0M	20.6M
2016	11.4M	12.5M	13.7M	14.8M
2015	0	0	0	10.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sensus Healthcare Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 11, 2024	sardano michael	acquired	-	-	20,000	president and general counsel
Dec 19, 2023	martinez magdalena	sold (taxes)	-1,971	2.66	-741	chief operating officer
Sep 14, 2023	sardano joseph c	bought	28,773	2.8773	10,000	chief executive officer
Aug 28, 2023	sardano michael	bought	2,990	2.99	1,000	president and general counsel
Aug 08, 2023	sardano joseph c	bought	38,574	3.8574	10,000	chief executive officer
Aug 08, 2023	sardano michael	bought	3,777	3.7778	1,000	president and general counsel
Jul 31, 2023	rampolla javier	sold (taxes)	-11,923	3.03	-3,935	chief financial officer
May 11, 2023	heinrich john	bought	28,600	2.86	10,000	-
May 10, 2023	sardano joseph c	bought	23,735	2.995	7,925	chief executive officer
May 09, 2023	o'rear samuel	bought	52,669	2.9987	17,564	-

Which funds bought or sold SRTS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Sachetta, LLC	unchanged	-	-	247,351	0.12%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Janney Montgomery Scott LLC	unchanged	-	58,000	154,000	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-4,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.13	163,455	473,275	-%
Apr 16, 2024	GARRISON BRADFORD & ASSOCIATES INC	unchanged	-	27,000	72,000	0.07%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-319,411	1,838,560	-%
Mar 01, 2024	Creekmur Asset Management LLC	new	-	83,053	83,053	0.03%
Feb 15, 2024	Nantahala Capital Management, LLC	added	91.03	321,677	834,260	0.03%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	37,203	37,203	-%

Are Funds Buying or Selling SRTS?

Are funds buying SRTS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRTS

No. of Funds

Unveiling Sensus Healthcare Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	solot edwin lee	9.36%	1,533,281	SC 13G/A
Feb 10, 2023	solot edwin lee	9.49%	1,554,845	SC 13G/A
Feb 07, 2022	solot edwin lee	6.7%	1,115,109	SC 13G/A
Sep 10, 2021	solot edwin lee	5.0%	831,027	SC 13G

Recent SEC filings of Sensus Healthcare Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	DEF 14A	DEF 14A
Apr 18, 2024	PRE 14A	PRE 14A
Mar 15, 2024	10-K	Annual Report
Feb 08, 2024	8-K	Current Report
Feb 06, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	8-K	Current Report

Peers (Alternatives to Sensus Healthcare Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.2B	40.3B	-4.83%	-4.47%	32.75	4.57	-2.84%	-3.08%
BDX	67.8B	19.7B	-3.67%	-7.05%	50.87	3.44	4.82%	-17.56%
ALGN	21.7B	3.9B	-7.16%	-5.33%	46.88	5.53	5.72%	46.72%
BAX	18.8B	14.9B	-14.74%	-18.53%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	4.25%	23.63%	31.11	2.75	6.16%	35.06%
HSIC	8.7B	12.3B	-7.72%	-14.36%	20.93	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-14.65%	-39.45%	-12.84	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-11.18%	-30.75%	-62.82	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-3.46%	33.44%	-215.47	8.86	30.82%	65.60%
PDCO	2.3B	6.6B	-3.32%	-1.38%	11.88	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-5.95%	-6.55%	-2.02	0.43	7.73%	-1066.14%
ANIK	408.8M	166.7M	4.91%	6.74%	-4.95	2.45	6.67%	-456.34%
ANGO	250.7M	324.0M	2.96%	-26.18%	-1.3	0.77	-3.19%	-337.41%
APYX	49.5M	52.3M	-10.06%	-59.60%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-19.65%	334.38%	-0.3	0.97	5.77%	8.23%

Sensus Healthcare Inc News

Latest updates

Sensus Healthcare Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	222.4%	12,567	3,898	4,527	3,414	13,104	9,010	12,080	10,338	6,704	3,070	5,095	1,620	1,183	1,679	8,509	5,841	7,476	5,437	8,081	6,334	6,057
Gross Profit	293.7%	7,831	1,989	2,619	1,622	8,350	5,874	8,256	7,149	8,856	1,586	3,228	672	640	709	5,458	3,844	4,939	3,316	4,861	4,169	3,941
Operating Expenses	-42.0%	2,253	3,884	3,746	4,561	4,179	3,713	3,686	3,219	3,537	2,701	2,972	2,951	3,214	4,346	4,474	4,649	4,894	5,509	4,830	4,592	4,439
S&GA Expenses	-51.6%	625	1,290	1,595	2,099	1,576	1,807	1,728	1,218	1,336	1,068	1,349	1,034	1,162	1,791	2,453	2,124	1,995	2,530	2,385	1,972	1,960
R&D Expenses	-37.6%	676	1,083	822	1,098	1,159	746	827	728	1,106	661	844	941	1,148	1,225	950	1,568	1,935	1,966	1,485	1,713	1,565
EBITDA Margin	-Infinity%	0.00*	-	0.11*	0.23*	0.64*	0.73*	0.76*	0.71*	0.18*	-0.24*	-0.17*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-243	-381	1.00	1.00	-1.00	1.00	-	2.00	3.00	14.00	-	-	-	-	-	-	58.00	66.00
Income Taxes	1376.4%	1,596	-125	-502	-802	1,578	450	1,070	648	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	468.4%	5,806	-1,576	-882	-2,696	4,407	2,279	4,594	16,710	5,318	-1,115	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	189.1%	0.03*	-0.03*	0.10*	0.23*	0.63*	0.72*	0.75*	0.70*	0.15*	-0.31*	-	-	-	-	-	-	-	-	-	-	-
Net Income	390.1%	4,210	-1,451	-380	-1,894	2,829	1,829	3,524	16,062	5,318	-1,115	1,018	-1,692	-2,574	-3,587	1,039	-730	112	-2,121	102	-458	-540
Net Income Margin	155.3%	0.02*	-0.04*	0.08*	0.17*	0.54*	0.67*	0.70*	0.68*	0.15*	-0.40*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	519.0%	2,668	431	713	-6,186	-10,123	3,663	1,851	3,038	-1,818	-1,195	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.3%	54.00	51.00	52.00	53.00	57.00	55.00	56.00	54.00	32.00	26.00	26.00	26.00	28.00	28.00	30.00	32.00	37.00	36.00	36.00	34.00	33.00
Current Assets	8.0%	50.00	46.00	47.00	49.00	53.00	52.00	51.00	48.00	31.00	24.00	24.00	24.00	25.00	25.00	27.00	30.00	34.00	33.00	33.00	32.00	32.00
Cash Equivalents	13.0%	23.00	20.00	20.00	19.00	26.00	38.00	34.00	33.00	15.00	16.00	15.00	14.00	15.00	16.00	18.00	12.00	8.00	7.00	11.00	6.00	12.00
Inventory	-10.2%	12.00	13.00	10.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	5.00	5.00	4.00	3.00	2.00	2.00	2.00	2.00
Net PPE	10.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-18.3%	5.00	6.00	6.00	7.00	9.00	8.00	11.00	11.00	6.00	5.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	8.00	7.00	7.00
Current Liabilities	-19.5%	4.00	5.00	5.00	6.00	8.00	7.00	10.00	10.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	7.00	6.00	5.00	6.00
Shareholder's Equity	9.5%	49.00	45.00	46.00	46.00	48.00	47.00	45.00	42.00	26.00	21.00	20.00	20.00	21.00	20.00	22.00	25.00	28.00	27.00	27.00	27.00	26.00
Retained Earnings	163.4%	7.00	3.00	4.00	4.00	6.00	3.00	2.00	-1.88	-17.94	-23.26	-23.45	-23.18	-22.06	-23.08	-21.39	-18.81	-15.23	-16.26	-15.53	-15.65	-13.53
Additional Paid-In Capital	0.1%	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	40.00
Shares Outstanding	-0.1%	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	17.00	16.00	16.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	46.00	-	-	-	114	-	-	-	51.00	-	-	-	35.00	-	-	-	63.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	503.6%	2,668	442	742	-5,997	-10,113	3,723	1,896	3,082	-1,780	1,253	1,356	-1,115	-360	-2,641	2,133	434	460	-1,624	6,176	-7,117	-1,652
Share Based Compensation	-22.4%	52.00	67.00	66.00	143	50.00	40.00	40.00	57.00	90.00	206	59.00	60.00	62.00	37.00	131	155	150	158	158	155	158
Cashflow From Investing	-100.0%	-	31.00	-29.00	-189	-10.00	-60.00	-45.00	14,956	-38.00	-3.00	250	-80.00	-104	353	3,214	3,567	735	-2,903	-911	-1,817	-2,984
Cashflow From Financing	82.1%	-7.00	-39.00	-	6.00	-1,934	211	-978	273	-54.00	-63.00	-54.00	-60.00	-756	-	970	-3.00	-	-	-81.41	2,702	-
Buy Backs	100.0%	-	-27.00	-	-	-	-	-1,005	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SRTS Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) $ in Thousands	12 Months Ended
Consolidated Statements of Income - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 24,405	$ 44,532
Cost of sales	10,345	14,904
Gross profit	14,060	29,628
Operating expenses
Selling and marketing	5,608	6,329
General and administrative	5,156	5,008
Research and development	3,678	3,460
Total operating expenses	14,442	14,797
Income (loss) from operations	(382)	14,831
Other income:
Gain on sale of assets	42	12,779
Interest income, net	992	380
Other income, net	1,034	13,159
Income before income tax	652	27,990
Provision for income taxes	167	3,746
Net income	$ 485	$ 24,244
Net income per share – basic (in Dollars per share)	$ 0.03	$ 1.47
diluted (in Dollars per share)	$ 0.03	$ 1.46
Weighted average number of shares used in computing net income per share – basic (in Shares)	16,259,254	16,480,991
diluted (in Shares)	16,266,139	16,618,214

SRTS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 23,148	$ 25,520
Accounts receivable, net	10,645	17,299
Inventories	11,861	3,501
Prepaid inventory	2,986	6,261
Other current assets	888	660
Total current assets	49,528	53,241
Property and equipment, net	464	243
Deferred tax asset	2,140	1,713
Operating lease right-of-use asset, net	774	996
Other noncurrent assets	804	542
Total assets	53,710	56,735
Current liabilities
Accounts payable and accrued expenses	2,793	5,521
Product warranties	538	403
Operating lease liabilities, current portion	187	190
Income tax payable	37	890
Deferred revenue, current portion	657	693
Total current liabilities	4,212	7,697
Operating lease liabilities	596	830
Deferred revenue, net of current portion	60	139
Total liabilities	4,868	8,666
Commitments and contingencies
Stockholders’ equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding
Common stock, $0.01 par value – 50,000,000 authorized; 16,907,095 issued and 16,374,171 outstanding at December 31, 2023; 16,902,761 issued and 16,390,419 outstanding at December 31, 2022	169	169
Additional paid-in capital	45,405	45,031
Treasury stock, 532,924 and 512,342 shares at cost, at December 31, 2023 and December 31, 2022, respectively	(3,519)	(3,433)
Retained earnings	6,787	6,302
Total stockholders’ equity	48,842	48,069
Total liabilities and stockholders’ equity	$ 53,710	$ 56,735

About Sensus Healthcare Inc

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and TransDermal Infusion system. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body, as well as distributes laser devices. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

CEO	Mr. Joseph C. Sardano
WEBSITE	sensushealthcare.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	42

Sensus Healthcare Inc Frequently Asked Questions

What is the ticker symbol for Sensus Healthcare Inc? What does SRTS stand for in stocks?

SRTS is the stock ticker symbol of Sensus Healthcare Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sensus Healthcare Inc (SRTS)?

As of Fri May 03 2024, market cap of Sensus Healthcare Inc is 59.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRTS stock?

You can check SRTS's fair value in chart for subscribers.

What is the fair value of SRTS stock?

You can check SRTS's fair value in chart for subscribers. The fair value of Sensus Healthcare Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sensus Healthcare Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sensus Healthcare Inc a good stock to buy?

The fair value guage provides a quick view whether SRTS is over valued or under valued. Whether Sensus Healthcare Inc is cheap or expensive depends on the assumptions which impact Sensus Healthcare Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRTS.

What is Sensus Healthcare Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, SRTS's PE ratio (Price to Earnings) is 122.7 and Price to Sales (PS) ratio is 2.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRTS PE ratio will change depending on the future growth rate expectations of investors.